Contraline
Contraline is a clinical-stage biotechnology company developing two proprietary male contraceptive technologies: ADAM, a non-hormonal hydrogel vas-deferens implant, and NES/T Gel, a once-daily hormonal topical gel. The company targets men and couples seeking reversible contraception, with Phase 3 trials for NES/T planned for 2027.
- Company typePrivate
- Founded2015
- HeadquartersCharlottesville, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Contraline does
Contraline is a clinical-stage biopharmaceutical company developing male contraceptive technologies. Headquartered in Charlottesville, Virginia, the company operates with 11–50 employees and is led by co-founder and CEO Kevin Eisenfrats. Contraline targets the unmet need for reversible male contraception — a category in which approximately three-quarters of couples currently rely on female-only contraceptive methods. The company is pre-revenue, and both of its investigational products have not received approval from the FDA or any other regulatory authority.
The company is developing two candidates built on distinct technical platforms. The lead hormonal candidate, NES/T Gel, is a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone that suppresses sperm production while maintaining physiological testosterone levels. NES/T Gel completed a Phase 2b trial enrolling 462 couples across 17 global sites, and Phase 3 development is anticipated in 2027 — described as the first-ever Phase 3 trial of a pharmacological male contraceptive. The second candidate, ADAM, is a non-hormonal polyethylene glycol hydrogel injected into the vas deferens that blocks sperm transport via 10–20 nm pore architecture while permitting small-molecule diffusion; the hydrogel is designed to last 2+ years and liquefies at end-of-life to restore fertility. ADAM completed a Phase 1 trial in 25 participants in Australia.
Contraline's future revenue model is expected to rely on prescription pharmaceutical sales for NES/T Gel and ADAM, supplemented by licensing royalties in territories the company does not commercialize directly. The company holds exclusive worldwide rights to NES/T through a February 2026 license with the Population Council, which originally co-developed the technology with NICHD/NIH. To date, Contraline has raised approximately $92.5 million cumulatively across seed, Series A, and Series B rounds, with the most recent $92.5M Series B in June 2026 co-led by BVF Partners and RA Capital Management.
Contraline firmographics
Firmographics- Name
- Contraline
- Legal name
- Contraline, Inc.
- Website
- https://contraline.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Contraline is a clinical-stage biotechnology company developing two proprietary male contraceptive technologies: ADAM, a non-hormonal hydrogel vas-deferens implant, and NES/T Gel, a once-daily hormonal topical gel. The company targets men and couples seeking reversible contraception, with Phase 3 trials for NES/T planned for 2027.
- Ownership category
- akta.pro rank
Contraline industry classification
Industry- Product category
- Male Contraceptives
- akta.pro primary industry
- Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD)
Keywords
Where Contraline is headquartered
LocationHeadquarters
- HQ city
- Charlottesville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Contraline business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical Product Sales: Contraline is a clinical-stage biopharmaceutical company developing male contraceptives. The company expects to commercialize NES/T Gel and ADAM upon regulatory approval, likely generating revenue through prescription pharmaceutical sales. NES/T Gel holds exclusive worldwide rights from Population Council.
- Licensing Royalties: Contraline holds exclusive worldwide rights to develop and commercialize NES/T. Potential future licensing arrangements may generate royalty revenue in markets where Contraline does not commercialize directly.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Contraline product offering
Product offeringCore offering
Contraline is a clinical-stage biopharmaceutical company developing two investigational male contraceptive products: ADAM, a non-hormonal, long-lasting polyethylene glycol hydrogel implant injected into the vas deferens to block sperm transport, and NES/T Gel, a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone to suppress sperm production while maintaining normal testosterone levels. Both products are designed to be reversible and address the lack of appealing male contraceptive options.
Product overview
Contraline is developing a portfolio of male contraceptive products consisting of two investigational candidates: NES/T Gel and ADAM Implant. NES/T is a once-daily topical hormonal gel that suppresses sperm production through a novel combination of segesterone acetate (Nestorone) and testosterone, designed for short-term reversible contraception. ADAM is a long-lasting, non-hormonal hydrogel implant that provides contraceptive protection for up to 24 months through vas-occlusion, offering a 'set and forget' alternative. Together, these products aim to provide men with both short-acting and long-acting reversible contraceptive options, addressing the current lack of appealing male contraceptive methods.
Differentiator
Problem solved
Functional benefit
Brands
- NES/T Gel: An investigational daily topical gel combining segesterone acetate (Nestorone) with testosterone for reversible male contraception.
- ADAM
Products and services
- NES/T Gel An investigational once-daily topical gel combining segesterone acetate (Nestorone) with testosterone, designed to suppress sperm production while maintaining physiological testosterone levels. Applied to the shoulders and upper arms, the hormonal product is reversible upon discontinuation and targets men seeking short-term reversible contraception.
- ADAM Implant An investigational long-lasting, non-hormonal, reversible hydrogel contraceptive implant injected into the vas deferens to block sperm transport. The polyethylene glycol-based implant is effective for an estimated 2+ years before the hydrogel liquefies and restores fertility, offering men a minimally invasive outpatient procedure.
Quantifiable outcome
- NES/T Phase 2b: Demonstrated efficacy, tolerability, reversibility, and user acceptability in 462 couples across 17 global sites
- +2 more outcomes
Companies that use Contraline
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Contraline technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Contraline partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Population CouncilcoreContraline executed a global exclusive license agreement with Population Council for NES/T male contraception gel. The Population Council co-developed NES/T with NICHD/NIH and transfers all development and commercialization rights to Contraline for late-stage development and global regulatory approvals.
- NICHD/NIH (National Institute of Child Health and Human Development)coreThe Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the U.S. National Institutes of Health, co-developed NES/T with Population Council and provided research support for clinical trials.
- Male Contraceptive InitiativeminorMale Contraceptive Initiative provided support for NES/T development, advancing male contraceptive research.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Contraline competitors and assessment
Company assessmentDirect peers
- Eppin Pharma: Developing EP055, a non-hormonal male contraceptive targeting Eppin protein on sperm surface. Direct peer in non-hormonal male contraception research.
- NEXT Life Sciences: Developing Plan A, a non-hormonal vas-deferens occlusive male contraceptive using a similar approach to Contraline's ADAM implant. Most directly comparable competitor in the male contraceptive space.
- YourChoice Therapeutics: Developing YCT-529, an oral non-hormonal male contraceptive pill targeting the retinoic acid receptor. Direct competitor in male contraception with a different delivery mechanism.
Emerging players
- Revolution Contraceptives: Early-stage company developing reversible vas-deferens occlusion technology for male contraception. Competing approach to Contraline's ADAM with similar long-acting, non-hormonal positioning.
- Daré Bioscience: Clinical-stage biopharmaceutical company focused on women's reproductive health with multiple contraceptive and hormone therapy candidates. Comparable biotech business model in adjacent reproductive health category.
- Femasys: Biomedical company developing women's reproductive health products including permanent contraception (FemaSeed). Comparable as a clinical-stage reproductive health device/drug company.
- Antiva Biosciences: Clinical-stage biopharmaceutical company developing therapeutics in women's health, including HPV-related cervical pre-cancer. Comparable clinical-stage biotech model in reproductive health, though different therapeutic focus.
Broad incumbents
- Population Council: Global nonprofit research organization that originally co-developed NES/T with NICHD/NIH and licensed it to Contraline. Comparable as a contraceptive R&D organization and Contraline's key licensor.
- Organon: Global women's health company with extensive contraceptive portfolio (NuvaRing, Nexplanon, Cerazette). Likely strategic acquirer or competitor if it expands into male contraception.
- Bayer: Major pharmaceutical company with established contraceptive brands (Mirena, Yaz, Kyleena) and significant R&D resources. Potential acquirer and competitive threat in reproductive health.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Contraline social profiles
Digital presenceContraline financial estimates
Financial estimateRevenue estimate
Valuation estimate
Contraline leadership team
Management profileNumber of profiles
Profiles5 records
Contraline funding detail
Funding detailFunding overview
Funding rounds9 records
Investors33 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Contraline M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Contraline
What does Contraline do?
Contraline is a clinical-stage biopharmaceutical company developing two investigational male contraceptive products: ADAM, a non-hormonal, long-lasting polyethylene glycol hydrogel implant injected into the vas deferens to block sperm transport, and NES/T Gel, a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone to suppress sperm production while maintaining normal testosterone levels. Both products are designed to be reversible and address the lack of appealing male contraceptive options.
Is Contraline a public or private company?
Contraline is a private company. It is classified as venture growth investor backed and is currently operating.
When was Contraline founded?
Contraline was founded in 2015. It employs 11 to 50 people.
Where is Contraline based?
Contraline is headquartered in Charlottesville, United States, in the North America region.
How does Contraline make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties.
Who are Contraline's main competitors?
Direct peers on record are Eppin Pharma, NEXT Life Sciences and YourChoice Therapeutics. Emerging players are Revolution Contraceptives, Daré Bioscience, Femasys and Antiva Biosciences. Broad incumbents are Population Council, Organon and Bayer.
Does Contraline have an API?
No public API is recorded for Contraline.
What industry is Contraline in?
Contraline's product category is Male Contraceptives. Its primary akta.pro industry code is HLAKAOAD, Male Reproductive & Sexual Medicine (Andrology).